Fusion genes associated with progressive prostate cancer

Patent metadata

Field	Value
Publication number	US-2018187268-A1
Application number	US-201815896818-A
Country	US
Kind code	A1
Filing date	Feb 14, 2018
Priority date	Dec 30, 2013
Publication date	Jul 5, 2018
Grant date	—

Abstract

The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.

First claim

What is claimed is:

1 . A method of treating a subject, comprising (i) determining whether a subject is at increased risk of manifesting progressive prostate cancer comprising determining whether a prostate cancer cell of the subject contains a SLC45A2-AMACR fusion gene; and (ii) where the cell contains the SLC45A2-AMACR fusion gene so that the subject is at increased risk, performing one or more of cryotherapy, radiation therapy, chemotherapy, hormone therapy, and radical prostatectomy.

2 . The method of claim 1 , wherein the fusion gene is detected by fluorescence in situ hybridization (FISH) analysis.

3 . The method of claim 1 , wherein the fusion gene is detected by polymerase chain reaction (PCR).

4 . The method of claim 1 , wherein the fusion gene is detected by Western blot analysis.

5 . The method of claim 1 , wherein the subject is determined to be at increased risk of rapid relapse.

6 . The method of claim 1 , wherein the subject is determined to be at increased risk of relapse.

7 . The method of claim 1 , further comprising determining a nomogram score of the subject.

8 . A method of treating a subject, comprising:
(i) determining whether a subject is at increased risk of manifesting progressive prostate cancer comprising determining whether a prostate cancer cell of the subject contains a SLC45A2-AMACR fusion gene; and (ii) where the cell contains the SLC45A2-AMACR fusion gene so that the subject is at increased risk; (a) administering a therapeutically effective amount of an inhibitor of the SLC45A2-AMACR fusion protein; (b) administering a therapeutically effective amount of an agent that inhibits the SLC45A2-AMACR fusion protein; (c) administering a therapeutically effective amount of an siRNA targeting the SLC45A2-AMACR fusion gene contained within the prostate cancer cell; (d) administering a therapeutically effective amount of an anti-cancer agent selected from the group consisting of chemotherapeutic agents, radiotherapeutic agents, cytokines, anti-angiogenic agents, apoptosis-inducing agents, and anti-cancer immunotoxins; and/or (e) performing a targeted genome editing procedure on one or more prostate cancer cells within the subject.

9 . The method of claim 8 , wherein the fusion gene is detected by fluorescence in situ hybridization (FISH) analysis.

10 . The method of claim 8 , wherein the fusion gene is detected by polymerase chain reaction (PCR).

11 . The method of claim 8 , wherein the fusion gene is detected by Western blot analysis.

12 . The method of claim 8 , wherein the subject is determined to be at increased risk of rapid relapse.

13 . The method of claim 8 , wherein the subject is determined to be at increased risk of relapse.

14 . The method of claim 8 , wherein a therapeutically effective amount of an inhibitor of the SLC45A2-AMACR fusion protein is administered.

15 . The method of claim 14 , wherein the inhibitor of the SLC45A2-AMACR fusion protein is selected from the group consisting of ebselen, 2-(2,5-dihydroxy-4-methylphenyl)-5-methyl benzene-1.4-diol (DMPMB), 2-methylsulfanyl-7,9-dihydro-3H-purine-6,8-dithione (MSDTP), 2,5-di(pyrazol-1-yl)benzene-1,4-diol (DPZBD), Rose Bengal, Congo Red, 3,5-di(pyridin-4-yl)-1,2,4-thiadiazole (DPTD), ebselen oxide, 3,7,12-trihydroxycholestanoyl Coenzyme A (THCA-CoA), N-methylthiocarbamate, trifluoro-ibuprofen and combinations thereof.

16 . The method of claim 14 , wherein the inhibitor of the SLC45A2-AMACR fusion protein is a racemase inhibitor.

17 . The method of claim 14 , wherein the inhibitor of the SLC45A2-AMACR fusion protein is an AMACR inhibitor.

18 . The method of claim 16 , wherein the racemase inhibitor is ebselen.

19 . The method of claim 16 , wherein the method further comprises administering a therapeutically effective amount of an AMACR inhibitor.

Assignees

• Univ Pittsburgh Commonwealth Sys Higher Education

Inventors

• Luo Jianhua
• Yu Yangping
• Nelson Joel B
• Michalopoulos George Konstantine
• Tseng Chien-Cheng
• Ding Ying

Classifications

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title